Schedule 13D/A (Amendment No. 5) – Sinovac Biotech Ltd. (SVA) details the current ownership position and voting intentions of 1Globe Capital LLC and its affiliate 1Globe Biomedical (Hong Kong) Co. Ltd. Ownership snapshot : Proxy contest stance : On 27 June 2025, Dr. Chiang Li (chairman of Sinovac and of both reporting entities) cast his 6.81 million directly-held shares " AGAINST " two proposals to (1) remove the current board (other than Dr. Li) and (2) install a new slate nominated by shareholder SAIF. 1Globe instructed affiliates to vote a further 11.7 million shares against both proposals, aligning roughly one-third of all votes with the incumbent board ahead of the 8 July 2025 special meeting. Litigation & share-count dispute : Ownership percentages exclude "Exchange Shares" and the "Disputed PIPE" securities issued after May 2018, whose validity is being litigated.